← Leaderboards
Marvin J Meyers
Saint Louis University
$5,628,117
Attributed
$12,392,909
Total exposure
8
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,392,909 · 8
By mechanism
R01$9,762,054 · 4
R33$1,343,491 · 1
R21$1,287,364 · 3
Top collaborators
- Christopher D Huston10 shared
- John E Tavis7 shared
- Cynthia Schieck Dowd5 shared
- David Griggs5 shared
- Francis Michael Sverdrup5 shared
- Damian J Krysan2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsIn VivoLeadPharmaceutical ChemistryBaseLead OptimizationMalariaDrug TargetingDrug KineticsPropertyChronicInfectionAnalogNovel TherapeuticsLifeStructure-Activity RelationshipAffectToxicologySeriesIn VitroPermeabilityPublic HealthPharmacologyStructure
Grant awards (27)
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$661,369
R01 · FY2025 · AI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$642,207
R01 · FY2024 · AI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$699,764
R01 · FY2023 · AI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$637,836
R01 · FY2023 · AI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$447,404
R33 · FY2023 · AI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$697,491
R01 · FY2022 · AI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$656,876
R01 · FY2022 · AI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$441,321
R33 · FY2022 · AI
Hit-to-lead optimization of broad spectrum antifungal phenothiazines$190,875
R21 · FY2022 · AI
Lead optimization of Hepatitis B Virus ribonuclease H inhibitors$654,955
R01 · FY2021 · AI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$620,271
R01 · FY2021 · AI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$454,766
R33 · FY2021 · AI
Hit-to-lead optimization of broad spectrum antifungal phenothiazines$243,125
R21 · FY2021 · AI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$620,271
R01 · FY2020 · AI
Inhibition of MEP pathway Isoprenoid Biosynthesis$513,396
R01 · FY2020 · AI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$230,252
R21 · FY2020 · AI
Preclinical optimization of a parasiticidal drug for cryptosporidiosis$691,919
R01 · FY2019 · AI
Inhibition of MEP pathway Isoprenoid Biosynthesis$516,446
R01 · FY2019 · AI
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development$206,487
R21 · FY2019 · AI
Inhibition of MEP pathway Isoprenoid Biosynthesis$513,396
R01 · FY2018 · AI
Defining approaches for improving HID and HPD compounds as HBV RNaseH antagonists$189,375
R21 · FY2018 · AI
Inhibition of MEP pathway Isoprenoid Biosynthesis$513,396
R01 · FY2017 · AI
Defining approaches for improving HID and HPD compounds as HBV RNaseH antagonists$227,250
R21 · FY2017 · AI
Inhibition of MEP pathway Isoprenoid Biosynthesis$555,821
R01 · FY2016 · AI
Aspartic Protease Inhibitors as Novel Antimalarials$186,380
R01 · FY2015 · AI · contact PI
Aspartic Protease Inhibitors as Novel Antimalarials$193,880
R01 · FY2014 · AI · contact PI
Aspartic Protease Inhibitors as Novel Antimalarials$186,380
R01 · FY2013 · AI · contact PI